Depo Provera Leads for Law Firms - Since 2009

Depo Provera Leads for Law Firms

Looking for Depo Provera leads? We deliver exclusive, imaging-verified meningioma claimants and signed retainers for plaintiff firms. A tentative global settlement was announced in MDL 3140 in June 2026 - intake is still open, but the deal isn't finalized and statutes of limitation are still expiring. Every lead is brand-verified, MRI/CT-confirmed, and screened to your firm's criteria. If a lead doesn't match what you asked for, we replace it free.

Request Live Inventory & Pricing Call (800) 889-1679

60K+Leads Delivered

3–5Days to First Lead

15+Years Experience

Depo Provera Lead Generation: The Opportunity Most Firms Are Misreading

Depo Provera Leads: The Window Didn't Close - It Changed Shape

If you're buying Depo Provera leads off pages written in spring 2026, you're reading stale intel. The story those pages tell - "early-stage MDL, build your docket before the bellwethers" - ended on June 15, 2026, when Judge M. Casey Rodgers announced a tentative global settlement in MDL 3140 and vacated the December bellwether trial.

Here's what didn't change: firms are still signing Depo-Provera cases, and the deadlines that matter to claimants are still running. The agreement isn't finalized, terms aren't public, and not every filed case is guaranteed a seat at the table. Statutes of limitation - as short as one year from diagnosis in some states - don't pause for settlement talks.

That's the real opportunity now for Depo Provera lead generation. The acquisition game is no longer "accumulate volume and wait for trials." It's "identify genuinely qualified claimants and get them properly signed and filed before eligibility hardens." That rewards quality, speed, and documentation - exactly what we built our intake around.

Request a No-Obligation Quote Call Us Now

By the Numbers

Depo-Provera Litigation Snapshot

5,500+Federal MDL Cases

MDL 3140N.D. Florida

June '26Tentative Settlement

No-Cost Replacement Guarantee If a lead doesn't match your criteria, we replace it.

Why This Window Still Matters

Depo Provera Leads: A Tentative Settlement, an Open Docket

The litigation reached its turning point fast - but the door to qualified, well-documented cases hasn't shut. Here's what that looks like on the ground.

Depo Provera leads - MDL 3140 litigation status, Northern District of Florida, June 2026 tentative global settlement

Depo Provera Lead Generation: The Settlement Is the Trigger

A tentative global settlement was announced in MDL 3140 in June 2026 - yet the deal isn't finalized and intake remains open. Firms that sign qualified claimants now are positioning before eligibility hardens.

Quality Is Now the Whole Game

Statutes of limitation are still running and documentation decides which cases survive. Every claimant we deliver is brand-verified, imaging-confirmed, and screened against the criteria that hold up under defense scrutiny.

Know the Litigation You're Entering

Depo Provera Litigation: Who You're Suing & What the Claims Allege

A Depo-Provera lead isn't generic - the product used, the diagnosis, and the timeline all determine whether a case is viable and where it gets filed. The litigation centers on one dominant defendant and one signature injury.

1 Pfizer Inc. - primary defendant. Holds the New Drug Application for Depo-Provera and is responsible for the drug's labeling. Related entities including Pharmacia & Upjohn and generic manufacturers are also named, but liability runs to brand-name exposure.

2 Meningioma - the signature injury. Plaintiffs allege long-term use of medroxyprogesterone acetate promotes the growth of intracranial (and sometimes spinal) meningiomas, confirmed by MRI or CT, often requiring surgery or radiation.

3 Failure to warn. The core allegation is that Pfizer failed to warn U.S. patients of the meningioma risk for decades - a posture strengthened when the FDA added a meningioma warning to the label in December 2025.

Get Pricing for Any Track

Litigation Landscape

MDL No. 3140N.D. Florida (Pensacola) · Judge M. Casey Rodgers

Pfizer Inc.Brand-name Depo-Provera & Depo-subQ Provera

Intracranial MeningiomaMRI/CT confirmed · WHO Grade I–III

★

State-Court DocketsDelaware, New York, California, Minnesota & more

June 2026Tentative global settlement · intake still open

The Science & Theories Driving This Tort

What Makes Depo Provera Leads Viable

The causation foundation in Depo-Provera is among the strongest in pharmaceutical litigation - peer-reviewed epidemiology plus a regulatory action that undercut the defense's central argument.

Pillar	What It Establishes
BMJ Study (2024)	A French case-control study found roughly a 5.5–5.6× increased risk of intracranial meningioma in women using the drug for more than one year - a core anchor for general causation.
JAMA Neurology (Sept 2025)	A Cleveland Clinic analysis of more than 10 million women confirmed an elevated risk (~2.4×) for long-term users, reinforcing the epidemiological link.
FDA Label Change (Dec 2025)	The FDA approved a meningioma warning for U.S. Depo-Provera labels - widely credited with weakening Pfizer's federal-preemption defense and driving the filing surge.
Failure to Warn	Plaintiffs allege Pfizer knew or should have known of the risk and failed to warn U.S. patients for decades, while warnings appeared earlier in other countries.

Qualifying Criteria for Law Firms

How We Qualify & Sort Every Depo Provera Lead

The qualifying bar in Depo-Provera is high - and that's good. A confirmed brain-tumor diagnosis filters out most inquiries before they reach intake. We screen for the facts that actually determine whether a case survives defense scrutiny.

Screening Step	What We Verify
Brand-Name Exposure	Confirmed use of Pfizer-branded Depo-Provera or Depo-subQ Provera. Because liability runs to the brand, we screen out unconfirmed generic-only use that weakens causation.
Duration Threshold	Minimum of roughly one year of use - about four injections - aligned with the risk cohort in the published studies. Single-shot inquiries are rejected at the funnel.
Imaging-Confirmed Meningioma	A diagnosed intracranial or spinal meningioma confirmed by MRI or CT - not headaches, not "symptoms." We exclude unrelated conditions such as glioblastoma or migraine without a tumor.
Timing Correlation	Use-duration mapped against diagnosis date to support causation and position the claim against the applicable statute of limitations.
Records Pathway Check	Because some exposure dates back decades, we flag record accessibility - pharmacy, physician, and insurer - before delivery, so your intake team isn't chasing 20-year-old records blind.
Compliance & Consent	TCPA consent documented with TrustedForm/Jornaya, identity and fraud screening on every contact, and HIPAA-aware intake throughout.

Why Choose Injury Case Claims

Why Firms Source Depo Provera Leads From Us

We've provided over 60,000 high-quality leads to satisfied law firms for more than 15 years. That same screening discipline now powers our Depo Provera lead generation - because in this tort, documentation quality, not raw volume, decides whether a case holds up.

Current to the Settlement, Not 2025

Most vendors are still selling a "ground-floor, build before the bellwethers" thesis that ended in June 2026. We update our qualification logic to the litigation as it stands today, and tell you the truth about case posture.

Verified Claimants, Not a List of Names

Every lead is brand-verified and imaging-screened by a non-incentivized intake specialist before delivery, with identity verification and fraud screening on every contact.

Replacement With No Deadline

If a lead doesn't match the criteria your firm sets, we replace it at no cost. We don't put an arbitrary window on that guarantee.

Fast Time to Lead

Most campaigns move from signed agreement to first delivered lead in three to five days - speed that matters while SOLs are still running.

Exclusive, Never Resold

Our exclusive inventory is sold to one firm only. You're not fighting other firms over the same claimant - you're the only call they expect. Signed-retainer and qualified-lead models are also available.

Fifteen-Plus Years in Mass Tort Leads

We've delivered more than 60,000 leads to law firms since 2009, across mass tort, motor vehicle accident, and personal injury dockets.

Choose the Model That Fits Your Capacity

Depo Provera Lead Types We Deliver

Every model can be filtered by geography, meningioma grade, surgical vs. monitored profile, and documentation depth - so the inventory matches your litigation strategy and your statute-of-limitations map.

Lead Type	Best For
Exclusive Leads	Sold to your firm only - never resold, never shared. You're the only call the claimant expects, with full ownership of the relationship.
Signed Retainers / Signed Cases	Fully executed retainer agreements plus HIPAA authorizations, delivered to your CRM (Filevine, Litify, and others) ready for filing.
Qualified-Lead Packages	Pre-vetted, high-intent claimants for firms that run their own intake and conversion and want to control the final sign step.

Discuss the Right Model

What This Tort Costs - Straight Talk

Depo Provera Lead Costs & Why the Economics Still Work

We won't pretend Depo-Provera is cheap. Firms researching this space deserve real numbers, not vague promises - and the published benchmarks tell a clear story about why the math holds.

Market Signal	What It Means for Your Firm
Cost Per Signed Case ≈ $5,000+	Published industry benchmarks put cost-per-signed-retainer among the highest of any active tort - figures around $5,000+ per signed case. The reason is the qualifying bar itself: a confirmed brain-tumor diagnosis filters out most inquiries.
The Screening Is a Feature	That high bar is why the economics work. A single qualified surgical case carries projected value many multiples above acquisition cost. Settlement terms aren't public, so any case-value figures are third-party estimates, not guarantees.
Priced to Your Criteria	We price by lead type, documentation depth, exclusivity, and geography - so you know exactly what you're paying for before the first lead arrives, rather than a flat rate regardless of how loosely "qualified" is defined.
The Window Rewards Documentation	With a global settlement being finalized, eligibility for newly-signed cases will only get more contested. Documentation quality is now the whole game - which is precisely what our intake is built to deliver.

Get Today's Pricing

Full Compliance

Depo Provera Lead Compliance: Built on Industry Standards

Operating since 2009, we've developed processes that ensure potential leads are treated fairly and their privacy respected. In a medical-record-driven tort like Depo-Provera, that care matters more than ever. We achieve full compliance with TCPA, HIPAA, ABA, and federal and state statutes.

GDPR

HIPAA

TCPA

CCPA

ABA

GDPR

HIPAA

TCPA

CCPA

ABA

Decades of Experience

Get Depo Provera Leads From a Partner You Can Trust

A global settlement is being finalized - but it isn't final, and intake is still open. The firms that win this window are the ones signing genuinely qualified Depo Provera claimants before eligibility hardens. If you're looking for a Depo Provera lead generation partner that delivers leads you can build into real cases, count on the one that has provided more than 60,000 across areas of practice for nearly 20 years.

Request Live Inventory & Pricing Call (800) 889-1679

15 Years of Experience - Injury Case Claims

Get Started

Request Your Depo Provera Leads
Inventory & Pricing

If your firm is looking for authentic legal marketing for case leads for your Depo-Provera, mass tort, or Personal Injury docket, give us the opportunity to earn your business.

We promise the best quality with the industry's best return policy. No other company offers investment protection like we do.

✓ Brand-Verified, Imaging-Confirmed Claimants

✓ Free Replacement if a Lead Doesn't Match Your Criteria

✓ 60,000+ Leads Delivered Since 2009

✓ Non-Incentivized Intake Specialists

✓ Exclusive - Leads Are Never Resold

✓ TCPA, HIPAA & ABA Compliant

10:11

Recent Leads

Recent Leads Appointments Notifications

Real-Time Leads

Instant updates so you never miss an opportunity.

Qualified Cases

Every lead is pre-screened and ready to convert.

Maximum Results

Our technology connects you with high-value cases.

Secure & Reliable

Your data and leads are always protected.

Experience Matters

EST. 2009 ★★★★★

First Name

Last Name

Law Firm Name

Email Address

Phone Number

Depo-Provera Lead Type of Interest

Tell us about your needs

By submitting, you consent to be contacted by InjuryCaseClaims.com regarding your inquiry. This does not constitute a binding agreement. All information is handled securely and confidentially.

FAQ

Depo Provera Leads - Frequently Asked Questions

Everything your firm needs to know before buying Depo Provera leads or launching your first campaign with Injury Case Claims.

No. As of late June 2026 the global settlement announced in MDL 3140 is tentative and not finalized, and firms are still actively signing and filing cases. What has changed is the emphasis: documentation quality and speed now matter more than raw volume. We screen specifically for cases that hold up under that scrutiny.

Federal cases are consolidated in MDL No. 3140, In re: Depo-Provera (Medroxyprogesterone Acetate) Products Liability Litigation, in the U.S. District Court for the Northern District of Florida before Judge M. Casey Rodgers. Parallel state-court dockets are active in Delaware, New York, California, Minnesota, and several other states.

The primary defendant is Pfizer Inc., which holds the New Drug Application for Depo-Provera. Related entities, including Pharmacia & Upjohn and generic manufacturers, are also named. Liability centers on brand-name exposure, which is why brand verification is a core screening step.

Generally: confirmed brand-name Depo-Provera or Depo-subQ Provera use of roughly one year or more (about four injections), an MRI- or CT-confirmed intracranial or spinal meningioma, and a claim within the applicable statute of limitations. We verify each of these before delivery.

Pricing depends on lead type, exclusivity, documentation depth, and geography. This tort carries one of the highest cost-per-signed-case figures in mass tort right now because the qualifying diagnosis - a confirmed brain tumor on imaging - filters out most inquiries. We provide current numbers and live inventory on request.

No, and be cautious of anyone who does. Settlement terms aren't public and eligibility for newly-signed cases isn't guaranteed. What we guarantee is qualification rigor: claimants screened against the criteria that make a case viable in this litigation.

We replace it at no additional cost. If a lead doesn't match the criteria your firm set, it gets replaced.

Yes. Our exclusive inventory is sold to one firm only and never resold or shared. When a claimant who meets your criteria contacts us, their information goes to you and only you. Signed-retainer and qualified-lead models are also available.